Lydia T. Buer
Oslo, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study.
Journal: Crohn's & colitis 360
Published: August 08, 2023
Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring.
Journal: Scandinavian journal of gastroenterology
Published: February 17, 2023
Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort.
Journal: Scandinavian journal of gastroenterology
Published: January 17, 2019
Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
Journal: Scandinavian journal of gastroenterology
Published: June 02, 2018
Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series.
Journal: Inflammatory bowel diseases
Published: September 21, 2017
Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?
Journal: Digestive diseases (Basel, Switzerland)
Published: February 02, 2017
Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study.
Journal: Journal of Crohn's & colitis
Published: July 26, 2016
How does kidney transplantation affect the relationship between donor and recipient?
Journal: Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke
Published: January 14, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026